Skip to main content

omeprazole

Generic: OMEPRAZOLE·Brand: Konvomep, OMEPRAZOLE, PRILOSEC, Prilosec, Primeguard, Talicia, UlcerGard, Yosprala, Zegerid Reformulated Aug 2006

omeprazole: 4 clinical trials tracked.

omeprazole evidence translation

What we can confirm

4 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about omeprazole, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 4 study sponsors
Clinical Trials (4)

Phase 1, 2-Cohort, Open-label, Fixed-sequence, Drug-drug Interaction Study to Evaluate the Effect of Repotrectinib on the Pharmacokinetics of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

NCT07223671·Phase 1·BMY
Completed

Primary endpoint: Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of AUC (0-T) of Probe Substrate With Repotrectinib

Interventionalopen30 enrolledStarted 2025-12Completion 2026-031 site · United StatesBristol-Myers Squibb

An Open-label, Drug-drug Interaction Study to Investigate the Effects of Amlitelimab on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Participants With Moderate-to-severe Atopic Dermatitis

NCT06686628·Phase 1·SNY
Completed

Primary endpoint: AUC and AUClast for CYP substrates

Interventionalopen23 enrolledStarted 2024-11Completion 2026-041 site · GermanySanofi

Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism: Pilot Randomized Study (RADIANT Study)

NCT06393868·Phase 3·GHRS
Recruiting

Primary endpoint: Study feasibility at participating centres

InterventionalRandomizedquadruple360 targetStarted 2024-11Completion 2028-037 sites · CanadaOttawa Hospital Research Institute

A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Oral Doses of GS-4571 in Healthy Participants, Multiple Ascending Oral Doses of GS-4571 in Nondiabetic Obese Participants and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM), and to Evaluate the Effect of Food and an Acid-Reducing Agent on Pharmacokinetics of GS-4571

NCT06562907·Phase 1·GILD
Recruiting

Primary endpoint: Single-Dose PK Parameter AUCinf of GS-4571

InterventionalRandomizeddouble134 targetStarted 2024-08Completion 2026-113 sites · United StatesGilead Sciences